TrialAlimentary pharmacology & therapeutics2019

Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation.

Mark T Osterman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.